Activist investor Starboard Value urges Becton Dickinson (BDX) to spin off its Life Sciences division, arguing it's undervalued within the larger company. BDX, a global medical technology firm, operates MedTech (infusion pumps, prefilled syringes, etc.) and Life Sciences (diagnostics, lab equipment). Starboard highlights the disparity in growth rates and valuation multiples between the two divisions, suggesting separation would unlock significant value for shareholders.
develops, manufactures and sells medical supplies, devices, laboratory equipment and diagnostic products for health-care institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry and the public worldwide.
Starboard is a very successful activist investor and has extensive experience helping companies focus on operational efficiency and margin improvement. Starboard also has significant experience with its strategic activism. In 57 prior campaigns where it had a strategic thesis, the firm had a 32.96% return versus 14.61% for the Russell 2000 during the same period. Additionally, Starboard has initiated activist campaigns at 24 prior health-care companies and its average return on these situations is 17.65% versus an average of 9.57% for the Russell 2000 during the same time periods.On Feb. 3, Starboard announced it has taken a position in Becton Dickinson and called for the separation of its life sciences division. Days later, on Feb. 5, the companyBecton Dickinson is a global medical technology company comprised of essentially two businesses: MedTech, which consists of the BD Medical and BD Interventional and BD Life Sciences, which provides products for the collection and transport of diagnostics specimens as well as instruments and reagent systems to detect a range of infectious diseases. Within MedTech, BDX is the market leader in the infusion pumps and prefilled syringes businesses, a position which has been supercharged by the growth in popularity of GLP-1s. These two businesses have historically been similar in size, but MedTech has been growing faster and now accounts for $15.1 billion of revenue and $6.7 billion of earnings before interest, taxes, depreciation and amortization versus Life Sciences contributing $5.2 billion of revenue and $2.0 billion of EBITDA. The problem here is simple and straightforward: The company operates two distinct businesses that are at different stages with different growth rates and valuation multiples and no real reason to be under the same roof. The MedTech business has a higher growth rate than Life Sciences but a lower valuation multiple than Life Sciences because MedTech is assessed as a rule of 40 company – that is, its growth rate plus its operating margins should equal or exceed 40. Life Sciences is seen as more structurally stable and immune to things like cyclicality, and it has reduced exposure to reimbursement pressure. Additionally, the presence of major industry players like Thermo Fisher and Danaher give the Life Sciences business a little consolidation value that slightly boosts its valuation multiple. This is not always a problem, but in BDX's case, the entire company is trading at 16.8-times EBITDA, closer to the value of its least valuable part. As Starboard has recommended, spinning off or selling the Life Sciences business is a simple solution to a simple problem. The short-term value creation here is straightforward. If separated, the Medtech Business should get a 13-times to 14-times EBITDA valuation based on its growth, while Life Sciences should get a valuation north of 20-times. This alone would result in a valuation north of $110 billion at the low end of the multiple range. But there is additional value creation that could be attained after separation. The ability to better motivate management with the success of their own division and expand the universe of potential investors to two pure-play businesses are just the table stakes in a separation. The real value comes from two separate management teams being able to better focus on and devote resources to their own businesses. In the case of BDX, that could lead to margin improvement through the integration of acquisitions that were somewhat neglected as part of a bigger company. There have been reports of a $30 billion valuation price for the Life Sciences business. This is a valuation slightly below the expected 20-times EBITDA multiple we think it could receive. We expect that is because BDX may retain some parts of the Life Sciences business that synergize with MedTech. This is not always a problem, but in BDX's case, the entire company is trading at 16.8-times EBITDA, closer to the value of its least valuable part. As Starboard has recommended, spinning off or selling the Life Sciences business is a simple solution to a simple problem. The short-term value creation here is straightforward. If separated, the Medtech Business should get a 13-times to 14-times EBITDA valuation based on its growth, while Life Sciences should get a valuation north of 20-times. This alone would result in a valuation north of $110 billion at the low end of the multiple range. But there is additional value creation that could be attained after separation. The ability to better motivate management with the success of their own division and expand the universe of potential investors to two pure-play businesses are just the table stakes in a separation. The real value comes from two separate management teams being able to better focus on and devote resources to their own businesses. In the case of BDX, that could lead to margin improvement through the integration of acquisitions that were somewhat neglected as part of a bigger company. There have been reports of a $30 billion valuation price for the Life Sciences business. This is a valuation slightly below the expected 20-times EBITDA multiple we think it could receive. We expect that is because BDX may retain some parts of the Life Sciences business that synergize with MedTech. Starboard is known as a very diligent, tenacious and committed activist investor that will do whatever is necessary to create value for its investors and other shareholders. When the firm wants board seats, it generally gets board seats. But that is not the case here. Starboard's"activist" skills might be wasted or not needed here as it appears that in this case, the firm is pushing an open door rather than breaking one down. BDX has already acknowledged this issue and announced that it isof its Life Sciences segment. Whether this is because the company has been considering this anyway or because it heard Starboard loud and clear is irrelevant. Starboard is the type of activist that does not care who gets the credit, as long as the best decisions are made for shareholders. Ken Squire is the founder and president of 13D Monitor, an institutional research service on shareholder activism, and the founder and portfolio manager of the 13D Activist Fund, a mutual fund that invests in a portfolio of activist 13D investments.Starboard takes a stake in Qorvo. How the activist may help improve margins
Starboard Value Becton Dickinson Spin-Off Activist Investor Medical Technology Life Sciences Medtech Valuation
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Mekhi Becton's Tears Highlight the Humanity of AthletesNew York Jets journeyman turned Philadelphia Eagles lineman Mekhi Becton's emotional outpouring during the Eagles' Week 17 playoff clinching victory speaks to the human side of professional athletes.
Read more »
Becton's First Playoff Appearance: Emotional Triumph for Eagles Right GuardMekhi Becton celebrates his first division title, playoff berth, and winning season as the Eagles secure their NFC East championship.
Read more »
Former Louisville OL Mekhi Becton Reaches NFC Championship with Philadelphia EaglesThe former Cardinal is just one win away from reaching the Super Bowl
Read more »
Morgan Stanley Sees 25.9% Upside for Qorvo After Activist Investor Starboard Value Takes StakeMorgan Stanley analyst Joseph Moore upgraded semiconductor and radio frequency chipmaker Qorvo to overweight from equal weight, citing the potential for a renewed earnings recovery path following the involvement of activist investor Starboard Value. Moore raised his price target by $16 to $106, suggesting a 25.9% potential upside for the stock. This upgrade comes after Qorvo shares rallied last week following the news that Starboard Value had unveiled a 7.7% stake in the company.
Read more »
Activist Investor Starboard Targets Qorvo for Margin ImprovementStarboard Value, a successful activist investor, has taken a 7.71% stake in Qorvo, a leading semiconductor company, and aims to improve the company's operational efficiency and margins. Starboard has a history of success in the semiconductor industry, and its involvement is likely to put pressure on Qorvo's management to address its financial performance.
Read more »
Starboard Pushes for Becton Dickinson Split, Citing Undervalued Life Sciences DivisionActivist investor Starboard Value LP calls for Becton Dickinson to separate its life sciences division, arguing that the two businesses operate at different stages and warrant distinct valuations. Starboard predicts significant value creation through this separation, highlighting the potential for higher valuations for both MedTech and BD Life Sciences.
Read more »